Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Clinical trial NCT03866382 · RECRUITING

Trial details

NCT number: NCT03866382
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Bladder Adenocarcinoma Bladder Clear Cell Adenocarcinoma Bladder Mixed Adenocarcinoma Bladder Neuroendocrine Carcinoma Bladder Small Cell Neuroendocrine Carcinoma Bladder Squamous Cell Carcinoma Chromophobe Renal Cell Carcinoma Collecting Duct Carcinoma Invasive Bladder Giant Cell Urothelial Carcinoma Invasive Bladder Lymphoepithelioma-Like Carcinoma Invasive Bladder Nested Urothelial Carcinoma Invasive Bladder Plasmacytoid Urothelial Carcinoma

Start date: 2019-05-13
Primary completion: 2027-02-28
Enrollment: 314

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.